Fexofenadine hydrochloride in the treatment of allergic disease: a review

Review

(4704) Views  (1463) Full article downloads

Authors: David Axelrod, Leonard Bielory

Published Date September 2008 Volume 2008:1 Pages 19 - 29

DOI: http://dx.doi.org/10.2147/JAA.S3092

David Axelrod¹, Leonard Bielory²

Division of Allergy, Immunology and Rheumatology, UMDNJ-New Jersey Medical School, ¹Department of Medicine, ²Departments of Medicine, Pediatrics, Ophthalmology and Visual Sciences, Newark, New Jersey, USA

Abstract: Fexofenadine is a selective, non-sedating H1 receptor antagonist, marketed in the United States since 2000. The FDA approved an oral suspension in 2006, for the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria in children. The tablet, capsule, and oral suspension are bioequivalent. Although fexofenadine does not use P450 CYP 3A4 it does interact with a number of drugs at P-glycoprotein and organic anion transporter polypeptides. The risk of toxicity from other drugs may increase with the administration of fexofenadine. Orange and grapefruit juices reduce the bioavailability of fexofenadine. Fexofenadine has been shown to have an impact on inflammatory mediators, other than histamine, such as decreasing the production of LTC₄, LTD₄, LTE₄, PGE₂, and PGF_2α; inhibiting cyclo-oxygenase 2, thromboxane; limiting iNOS generation of NO; decreasing cytokine levels (ICAM-1, ELAM-1, VCAM-1, RANTES, I-TAC, MDC, TARC, MMP-2, MMP-9, tryptase); and diminishing eosinophil adherence, chemotaxis, and opsonization of particles. These effects may provide benefit to some of the inflammatory responses of an acute allergic reaction and provide a basis for future development of H1 antagonists with stronger anti-inflammatory effects. These studies also support the contention that fexofenadine is effective for the treatment of allergic rhinits and chronic idiopathic urticaria.

Keywords: fexofenadine, allergy, oral suspension, formulations, pharmacology